• Jean-François Emile, Fleur Cohen-Aubart, Matthew Collin, Sylvie Fraitag, Ahmed Idbaih, Omar Abdel-Wahab, Barrett J Rollins, Jean Donadieu, and Julien Haroche.
• EA4340 BECCOH, Université de Versailles SQY, Service de Pathologie, Hôpital Ambroise Paré, AP-HP, Boulogne, France. Electronic address: jean-francois.emile@uvsq.fr.
• Lancet. 2021 Jul 10; 398 (10295): 157170157-170.

AbstractHistiocytoses constitute a heterogeneous group of rare disorders, characterised by infiltration of almost any organ by myeloid cells with diverse macrophage or dendritic cell phenotypes. Histiocytoses can start at any age. Diagnosis is based on histology in combination with appropriate clinical and radiological findings. The low incidence and broad spectrum of clinical manifestations often leads to diagnostic delay, especially for adults. In most cases, biopsy specimens infiltrated by histiocytes have somatic mutations in genes activating the MAP kinase cell-signalling pathway. These mutations might also be present in blood cells and haematopoietic progenitors of patients with multisystem disease. A comprehensive range of investigations and molecular typing are essential to accurately predict prognosis, which can vary from spontaneous resolution to life-threatening disseminated disease. Targeted therapies with BRAF or MEK inhibitors have revolutionised salvage treatment. However, the type and duration of treatment are still debated, and the prevention of neurological sequelae remains a crucial issue.Copyright © 2021 Elsevier Ltd. All rights reserved.

13 keywords...

hide…